Benjamin Jackson Sells 7,084 Shares of Sera Prognostics, Inc. (NASDAQ:SERA) Stock

Sera Prognostics, Inc. (NASDAQ:SERA) General Counsel Benjamin Jackson sold 7,084 shares of the company’s stock in a transaction that occurred on Thursday, May 8th. The shares were sold at an average price of $2.44, for a total value of $17,284.96. Following the completion of the transaction, the general counsel now directly owns 131,460 shares in the company, valued at approximately $320,762.40. The trade was a 5.11% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Benjamin Jackson also recently made the following trade(s):

• On Thursday, March 6th, Benjamin Jackson sold 2,285 shares of Sera Prognostics stock. The shares were sold at an average price of $4.16, for a total value of $9,505.60.

Sera Prognostics Stock Up 4.7%

Shares of SERA opened at $2.22 on Monday. The business’s 50 day moving average is $3.48 and its two-hundred day moving average is $5.49. Sera Prognostics, Inc. has a 52-week low of $2.10 and a 52-week high of $9.91. The firm has a market cap of $83.61 million, a price-to-earnings ratio of -2.24 and a beta of 0.99.

Sera Prognostics (NASDAQ:SERA) last announced its earnings results on Wednesday, May 14th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.04. The business had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.06 million. On average, equities analysts expect that Sera Prognostics, Inc. will post -0.96 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sera Prognostics

A number of institutional investors have recently made changes to their positions in the business. XTX Topco Ltd acquired a new position in shares of Sera Prognostics in the 1st quarter valued at approximately $39,000. Perkins Capital Management Inc. bought a new stake in shares of Sera Prognostics in the 1st quarter valued at approximately $522,000. Bank of New York Mellon Corp increased its holdings in shares of Sera Prognostics by 3.6% in the 1st quarter. Bank of New York Mellon Corp now owns 135,582 shares of the company’s stock valued at $499,000 after acquiring an additional 4,670 shares during the last quarter. Sanders Morris Harris LLC increased its holdings in shares of Sera Prognostics by 4.0% in the 1st quarter. Sanders Morris Harris LLC now owns 94,200 shares of the company’s stock valued at $347,000 after acquiring an additional 3,600 shares during the last quarter. Finally, Rhumbline Advisers increased its holdings in shares of Sera Prognostics by 10.7% in the 1st quarter. Rhumbline Advisers now owns 39,970 shares of the company’s stock valued at $147,000 after acquiring an additional 3,869 shares during the last quarter. 54.64% of the stock is owned by institutional investors and hedge funds.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.